Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Gilead Sciences in a report ...

Research analysts at Leerink Partnrs upped their Q3 2025 EPS estimates for shares of Waters in a note issued to investors on ...

Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market ...

Leerink Partners analyst Daina Graybosch maintained a Buy rating on Nkarta (NKTX – Research Report) yesterday and set a price target of $7.00.

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

A Leerink analyst says CVS is starting to benefit from stabilization in its Aetna health-insurance and pharmacy-benefits ...

Leerink analyst Michael Cherny upgraded CVS Health (CVS) to Outperform from Market Perform with a price target of $75, up from $55. The firm ...

Genmab (GMAB) and Sonic Automotive (SAH) are climbing 5% and 3%, respectively, after investment banks issued favorable notes ...

U.S. District Judge Angel Kelley for the District of Massachusetts allowed state law claims to move forward in a suit brought by an investment banker who claims Leerink Partners failed to pay minimum ...

Thryv Therapeutics Inc., a clinical-stage biotechnology company pioneering novel therapies for cardiovascular diseases, is ...

An investment banker who left Goldman Sachs & Co. for Leerink Partners LLC advanced part of her lawsuit saying she was denied ...